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Abstract
Purpose Generic health measures have been questioned for quantifying mental-health-related outcomes. In patients with 
anxiety and/or depression, our aim is to assess the psychometric properties of the preference-based EQ-5D-5L (generic 
health) and ReQoL-UI (recovery-focussed quality of life) for economic evaluation against the PHQ-9 (depression) and 
GAD-7 (anxiety). EQ-5D-5L anxiety/depression item and ReQoL-10 are also assessed.
Methods A 2:1 (intervention: control) randomised controlled trial collected measures at baseline and 8 weeks post baseline; 
in the intervention arm, data were also collected 3, 6, 9, and 12-months post baseline. EQ-5D-5L preference-based scores 
were obtained from the value set for England (VSE) and ‘cross-walked’ EQ-5D-3L United Kingdom (UK) value set scores. 
ReQoL-UI preference-based scores were obtained from its UK value set as applied to seven ReQoL-10 items. EQ-5D-5L 
and ReQoL measures’ construct validity and responsiveness were assessed compared against PHQ-9 and GAD-7 scores 
and group cut-offs.
Results 361 people were randomised to intervention (241) or control (120). ReQoL-UI/-10 had better construct validity with 
depression severity than the EQ-5D-5L (VSE/cross-walk scores), which had relatively better construct validity with anxiety 
severity than the ReQoL-UI/-10. Across all intervention-arm time-points relative to baseline, responsiveness was generally 
better for EQ-5D-5L (VSE in particular) than ReQoL-UI, but worse than ReQoL-10.
Conclusion There is insufficient evidence to recommend the ReQoL-UI over EQ-5D-5L for economic evaluations to capture 
anxiety severity. However, there may be rationale for recommending the ReQoL-UI over the EQ-5D-5L to capture depres-
sion severity given its better construct validity, albeit poorer responsiveness, and if recovery-focussed quality of life relative 
to condition-specific symptomology is the construct of interest.
Keywords EQ-5D-5L · ReQoL-10 · ReQoL-UI · Anxiety · Depression · Psychometrics · Economic evaluation
Plain English summary
Anxiety and depression disorders are ‘common’ mental 
health disorders, due to the high proportion of people they 
inflict. Condition-specific measures reported by those with 
these disorders exist to reflect condition-specific symptoms 
and severity. Alternatively, more ‘generic’ measures aim to 
capture broader aspects of physical and/or mental health in 
a single measure. Additionally, for allocating finite budg-
ets between alternative care interventions, measure scores 
that reflect ‘preference’ between alternative health states are 
recommended. Our study explored to what extent two pref-
erence-based measures captured condition-specific aspects 
of anxiety and depression: the EQ-5D-5L is a commonly 
used generic measure which focusses more of physical than 
mental health, whereas the ReQoL-UI is a newer ‘recovery-
focussed quality-of-life’ measure which focusses more of 
mental than physical health. Our findings suggest the com-
monly used EQ-5D-5L has benefits for capturing anxiety 
severity and was responsive as condition severity changed 
overtime, but the ReQoL-UI could be recommended over 
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the EQ-5D-5L to better capture depression severity and if 
‘recovery-focussed quality of life’ was of interest relative 
to condition-specific symptoms and severity. Overall, our 
findings suggest each measure has their roles for capturing 
aspects of anxiety and depression severity, but neither on 
their own captured the whole broad nature of anxiety and 
depressive disorders.
Introduction
The 2010 Global Burden of Disease study estimates depres-
sion and anxiety disorders contribute a large portion of total 
disability amongst all mental health and substance use dis-
orders, with increased societal costs through higher health-
care utilisation and absenteeism from work [1–4]. Mental 
health disorders have been estimated to represent 23% of 
the total cause of disability, higher than cancer and coronary 
heart disease [5]. In England, approximately 1/6 adults have 
a common mental disorder [6]. In the UK, prevalence of 
depressive and anxiety symptoms are significantly higher 
relative to pre-COVID-19 pandemic levels [7]. Therefore, 
prioritising mental health alongside other care interventions 
are important considerations for decision-makers.
Economic evaluation evidence helps inform resource 
allocation between alternative care interventions within 
a finite budget [8, 9]. Estimating the cost-effectiveness of 
mental health interventions has become an area of debate 
[8–10]. One aspect is the empirically demonstrated insen-
sitivities to mental health aspects of health-related quality 
of life (HRQoL) of generic health measures compared to 
condition-specific measures [9–12]. This includes EuroQol’s 
internationally used, preference-based EQ-5D three-level 
version (EQ-5D-3L) used for cost-utility analysis (CUA) 
and recommended by reimbursement agencies including the 
National Institute for Health and Care Excellence (NICE) for 
England and Wales [13, 14]. In CUA, HRQoL measured on 
a preference-based scale anchored at 1 (full health) and 0 
(a state equivalent to dead) is combined with length of life 
to generate quality-adjusted life years (QALYs), allowing 
comparisons between interventions that affect quantity and/
or quality of life. Results suggesting the appropriateness of 
generic measures in patients with mental health conditions 
are mixed, with better support in common (e.g. anxiety and 
depression) relative to severe (e.g. schizophrenia and bipolar 
disorder) mental health populations [11, 15–17]. Therefore, 
it has been argued that preference-based measures focussed 
on the impact of the mental disorder should be considered 
over generic measures which often focus more on physical 
than mental health [17, 18].
In response to the insensitivities of the EQ-5D-3L represent-
ing 243 (3-levels5-items) possible health states, the EQ-5D five-
level version (EQ-5D-5L) has been developed representing 
3125  (55) possible health states, with improved sensitivity and 
reduced ceiling effects [19–27]. Country-specific EQ-5D-5L 
preference-based value sets are available (https:// euroq ol. org/) 
with the current value set for England (VSE) based on a com-
bined composite Time Trade-Off (cTTO) and Discrete Choice 
Experiment (DCE) hybrid model for eliciting preferences 
[28–34]. However, an independent quality assurance study 
raised concerns about the VSE, with NICE’s interim position 
being to instead use the cross-walk algorithm by van Hout 
et al. [35–40]. Therefore, EQ-5D-5L preference-based values 
can be calculated using ‘cross-walked’/‘mapped’ EQ-5D-3L 
United Kingdom (UK) value set scores based on the conven-
tional TTO method [41]; however, cross-walk algorithms 
also have inherent concerns (e.g. predictive errors) [42–45]. 
EuroQol’s Blog provides updates for the new UK EQ-5D-5L 
valuation study [46].
The Recovering Quality-of-Life 20-item (ReQoL-20) and 
10-item (ReQoL-10) version have been developed as ‘recov-
ery-focussed quality-of-life’ measures for mental health ser-
vice users [18]. A UK preference-based value set using the 
cTTO method can be assigned to seven ReQoL-10 items: the 
ReQoL Utility Index (ReQoL-UI) representing 78,125  (57) 
possible health states as an alternative to the EQ-5D-5L for 
calculating QALYs in mental health service users [47]. The 
ReQoL-UI’s developers suggest that compared to the generic 
EQ-5D measures, it is a generic preference-based measure 
focussed more on mental than physical health [47]. Initial 
ReQoL-10 and ReQoL-20 psychometric analyses in a general 
and patient population (≈ 35%, common mental health prob-
lem) supported their internal consistency, test–retest reliability, 
construct validity, and responsiveness, concluding they per-
formed “markedly better than the EQ-5D[-3L]” [18]; however, 
such ReQoL-UI evidence does not currently exist.
Our aim is to assess the psychometric properties (con-
struct validity and responsiveness) of the preference-based 
EQ-5D-5L (VSE and cross-walk) and ReQoL-UI, compared 
to clinical measures for depression and anxiety: the Patient 
Health Questionnaire-9 (PHQ-9) and Generalised Anxiety 
Disorder-7 (GAD-7), respectively. Secondary psychometric 
analyses include the: (1) ReQoL-10, to compare its psycho-
metric properties relative to the preference-based measures; 
(2) EQ-5D-5L’s single mental health ‘anxiety/depression’ 
item, to assess its psychometric properties for depression 




Data were obtained from a parallel groups, randomised 
wait-list-controlled trial examining the effectiveness and 
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cost-effectiveness of internet-delivered Cognitive Behav-
ioural Therapy (iCBT) for depression and anxiety [50].
The study was conducted in step 2 of the Improving 
Access to Psychological Therapies (IAPT) program at the 
Berkshire National Health Service (NHS) Talking Thera-
pies Trust. Patients are referred to IAPT Step 2 if they are 
experiencing mild to moderate symptoms of depression or 
anxiety, at which point they are offered low-intensity psy-
chological interventions (e.g. computerised CBT) [51]. Trial 
participants were new IAPT referrals (June 2017–April 
2018). Eligibility criteria was applied before 2:1 (interven-
tion: 8-week waiting-list control) randomisation (Appendix 
S1). Trial inclusion criteria were people: (i) aged between 
18 and 80 years; (ii) above clinical thresholds for depression 
(PHQ-9 ≥ 10) or anxiety (GAD-7 ≥ 8) [52–54], and (iii) suit-
able for iCBT (i.e. willing to use iCBT, internet access). In 
addition, the structured Mini International Neuropsychiatric 
Interview 7.0.2 (M.I.N.I.) [55], administered by telephone 
by Psychological Wellbeing Practitioners (i.e. clinicians 
trained in the delivery of low-intensity support) established 
the presence or absence of a primary diagnosis of depression 
or anxiety disorder at baseline.
Upon showing interest in the study, participants received 
an email with the information about the trial and a link to 
give consent through their digital signature before sched-
uling their M.I.N.I. Trial ethics approval was provided by 
the NHS England Research Ethics Committee (REC Refer-
ence: 17/NW/0311). The trial was prospectively registered: 
Current Controlled Trials ISRCTN91967124. Current trial 
status is ‘completed’ with the protocol [50] and main results 
[56] published. The trial results showed that iCBT produced 
statistically significant improvements in depression (PHQ-9) 
and anxiety (GAD-7) symptomatology compared to wait-
list controls at 8-weeks, with further statistically significant 
improvements from 8-weeks up to 12-months for the inter-
vention group [56].
Outcome measures
Table 1 provides an overview description of the patient-
reported outcome measure (PROM) scores and constructs 
included for psychometric analysis. Measures were collected 
at baseline and 8 weeks post baseline in both trial-arms; in 
the intervention-arm, data were also collected at 3, 6, 9, and 
12 months post baseline.
Generic measures of physical and/or mental health
The EQ-5D-5L is a self-reported, generic health measure 
with five severity levels scored from 1 (best state) to 5 (worst 
state), over five dimensions/items: mobility; self-care; usual 
activity; pain/discomfort; anxiety/depression [25, 57]. The 
VSE and cross-walk ranges from − 0.285 or − 0.594, respec-
tively, to 1 [30, 38].
The ReQoL-10 consists of six positively worded (items: 
2, 4, 5, 7, 8, 10) and four negatively worded (items: 1, 3, 
6, 9) mental health items plus one physical health item to 
measure self-reported perception of own recovery-focussed 
quality of life across seven themes: autonomy; wellbeing; 
hope; activity; belonging and relationships; self-perception; 
physical health [18]. These themes align with the concept 
of ‘personal recovery’ and are based on outcomes mental 
health service users identified as being most central to them 
in recovering their quality of life; i.e. compared to recovery 
via reducing symptomatology as captured by the GAD-7 
and PHQ-9 (see ‘Condition-specific measures’) [18, 58, 59]. 
Each ReQoL-10 item is scored from 0 (worst state) to 4 (best 
state), with a summary score from 0 (poorest quality of life) 
to 40 (highest quality of life) [18].
The ReQoL-UI can be assigned to six-items (items: 3, 
5, 6, 7, 9, 10) and one physical health item of the ReQoL-
10, while retaining the original seven themes [47]. The UK 
value set score ranges from − 0.195 to 1 [47].
Condition‑specific measures
The PHQ-9 [54, 60] is a self-reported screening for depres-
sion measure reflecting the Diagnostic and Statistical 
Manual of Mental Disorders, Fourth Edition—Text Revi-
sion (DSM–IV–TR) criteria [61]. Items are scored from 0 
(best state) to 3 (worst state), with a summary score range 
from 0 (minimal depression) to 27 (severe depression). A 
PHQ-9 ≥ 10 has been shown to have a sensitivity of 88% and 
a specificity of 88% for major depression, with five estab-
lished depression severity cut-off points: “PHQ-9 scores 
of 5, 10, 15, and 20 represent valid and easy-to-remember 
thresholds demarcating the lower limits of mild, moderate, 
moderately severe, and severe depression” ([54], p. 611).
The GAD-7 [53] is a self-reported symptoms and severity 
of anxiety measure based on the DSM-IV GAD diagnostic 
criteria, with good internal consistency (α = .92) and con-
vergent validity with other anxiety scales [53]. Items are 
scored from 0 (best state) to 3 (worst state), with a summary 
score range from 0 (minimal anxiety) to 21 (severe anxiety). 
A GAD-7 ≥ 10 was originally suggested to represent a rea-
sonable cut-off for identifying GAD [53], but more recent 
studies have suggested using GAD-7 ≥ 8 [52, 62, 63]. The 
GAD-7 has four anxiety severity cut-off points: “Cut points 
of 5, 10, and 15 might be interpreted as representing mild, 
moderate, and severe levels of anxiety on the GAD-7, simi-
lar to levels of depression on the PHQ-9” ([53], p. 1095).
IAPT services have operationalised the aforementioned 
based on ‘caseness’ (PHQ-9 ≥ 10; GAD-7 ≥ 8) and ‘reli-
able change’ (PHQ-9 absolute change ≥ 6; GAD-7 absolute 
change ≥ 4) threshold values [52, 54, 64, 65]. Caseness is 
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the term used to describe a patient whose symptoms of 
anxiety or depression are severe enough to be considered 
a clinical case of that condition, whereas reliable change 
is a change between two scores on the same measure that 
would be regarded as a clinically significant change in 
the patient’s condition [65]. These thresholds are part of 
IAPT’s patient-based performance outcomes when measur-
ing ‘recovery’ (moving from ‘caseness’ to ‘no caseness’), 
‘reliable improvement’ (achieving ‘reliable change’ over a 
course of treatment), and ‘reliable recovery’ (achieving both 
‘recovery’ and ‘reliable improvement’) [65].
IAPT Phobia Scales (IAPT-PS) and Work and Social 
Adjustment Scale (WSAS) as routinely collected measures 
within IAPT services were included for analysis; these 
additional measures, analyses and associated results are 
described in the Supplementary Appendix [66–68].
Statistical analyses
The analyses use all observed cases; therefore, the sample 
size (N) varies dependent on the analysis being performed 
with relevant N values presented in the result tables. Con-
struct validity is assessed based on the whole cohort’s base-
line data, whereas responsiveness is assessed within trial-
arm across all available time-points. Statistical significance 
(SS), p < 0.05, with all analyses conducted in Stata 15 [69].
Table 1  Description of outcomes measures and associated scores
VSE value set for England
Long name Short name Construct Scoring type No. items Item score Floor/
worst
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Construct validity
Construct validity assesses the extent to which a measure 
reflects HRQoL differences hypothesised to exist. This is 
important in relation to preference-based PROMs used to 
elicit QALYs, as their values should reflect HRQoL fac-
tors linked to the condition/treatment being evaluated. Con-
struct validity is assessed despite no ‘gold standard’ HRQoL 
measure in mental health, given the difficulty in generating 
indicators that assess the full impact of mental health on 
people’s lives. Therefore, we assess a range of indicators to 
suggest, but cannot fully prove, construct validity in relation 
to convergent and known-group validity.
Convergent validity assesses the relationship between 
measures, based here on correlation analysis and locally 
weighted scatterplot smoothing (LOWESS) techniques. 
Spearman’s rank absolute correlation strength (ACS) coeffi-
cient and associated p-value as a non-parametric test, chosen 
post hoc based on the measures’ score distributions, indi-
cates the degree to which instruments are measuring related 
factors [70]. LOWESS complements the correlation analyses 
as a form of non-parametric regression which plots a line 
of central tendency between two variables on a scatterplot, 
thereby visualising their general relationship across the pos-
sible score ranges without making assumptions about the 
actual relationship [71].
Known-group validity assesses the extent to which instru-
ment scores differ between groups that are expected to differ, 
measured using Cohen’s d standardised absolute effect sizes 
(AES i.e. the difference in mean scores between two adja-
cent severity subgroups divided by the standard deviation 
of scores for the milder of the two subgroups) [70, 72]. The 
non-parametric Kruskal Wallis test complements assessing 
AES as it suggests if there is a statistically significant differ-
ence between the two or more known-groups.
Responsiveness
Responsiveness is important in economic evaluation as 
any change in health must be reflected by change in utility/
preferences, and subsequent change in QALYs. For exam-
ple, if HRQoL changes following an intervention, but the 
preference-based score does not change, this change will 
not be reflected in QALYs which could wrongly influence 
funding decisions.
To measure responsiveness we examined floor (worst pos-
sible score) and ceiling (best possible score) effects, which 
affect the ability of the measure to detect deterioration or 
improvements in health, respectively. We also examined the 
magnitude of change in scores over time as a crude indicator 
of responsiveness; however, we cross-referenced change in 
measure scores against the GAD-7 or PHQ-9 when reliable 
change had been achieved (PHQ-9 ≥ 6; GAD-7 ≥ 4) or not 
[67]. The assumption here is that if a change over time is 
observed on the condition-specific measures (general change 
or less/greater than the reliable change threshold), ideally 
we would want to observe a similar magnitude of change on 
the other measure scores whereby magnitude of change was 
assessed using standardised response mean (SRM i.e. divide 
the mean change on the measure by the standard deviation 
of the change) [70, 72].
Results
Descriptive statistics
Overall, 361 people were randomised (241 intervention-
arm: 120 control-arm). The majority of participants were 
female (71.5%), ‘White/White British and Irish’ ethnicity 
(84.2%), employed full-time (74.5%), not prescribed psy-
chiatric medication (51.5%), and not receiving statutory sick 
pay (93.4%). The M.I.N.I. classified 80.3% as having major 
depressive (52.4%) or anxiety disorder (64.0%), with 36.0% 
having both.
Table 2 presents baseline number of responders and 
PROM scores across the whole cohort and by trial-arm 
across all time-points in Table 3. At baseline, the PHQ-9 
and GAD-7 suffered no missing data with the EQ-5D-5L 
and ReQoL-10 being completed by 355 (98.3%) and 353 
(97.8%) participants, respectively. At follow-up time-points, 
the number of completed PROMs declined due to ‘lost to 
follow-up’ or ‘excluded’ from the study, or ‘unknown’ 
(mainly for EQ-5D-5L and ReQoL-10). As part of the trial-
based analyses, data missing at follow-up was classified as 
missing at random [56].
A Consort diagram, further demographic details, histo-
grams and additional score statistics are provided in Appen-
dices S1–4.
Construct validity
Table 4 ACS results and LOWESS graphs (Appendix S5) 
suggest that the ReQoL-UI/-10 have stronger convergent 
validity with depression than anxiety severity; stronger than 
the convergent validity results for the EQ-5D-5L scores with 
depression but not anxiety severity. The EQ-5D-5L scores 
have similar convergent validity with depression and anxi-
ety severity.
Table 5 AES results for caseness cut-offs suggest that 
the ReQoL-UI/-10 were better at quantifying a difference 
between depression than anxiety caseness, which the EQ-
5D-5L scores did better than the ReQoL-UI/-10 for anxiety 
caseness, but still with a small AES. The results for the EQ-
5D-5L depression/anxiety item suggests the item is better 
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at quantifying a difference between those with anxiety than 
depression caseness.
Table 5 AES results for severity cut-offs suggests the EQ-
5D-5L scores were better at quantifying a difference between 
‘severe’ relative to the next adjacent severity state than any 
other adjacent severity states on the PHQ-9 and GAD-7, 
and this AES tended to be larger than for the ReQoL-UI/-10 
(apart from on the PHQ-9 for ReQoL-10); however, the 
ReQoL-UI/-10 relative to EQ-5D-5L scores had higher 
AES between the adjacent lesser severe states (i.e. PHQ-9, 
‘moderately severe’ relative to ‘moderate’; GAD-7, ‘moder-
ate’ relative to ‘mild’). Additionally on the PHQ-9, the EQ-
5D-5L mean scores were greater for those in the ‘moderate’ 
than ‘mild’ state, which seems illogical and not in-line with 
the other measures’ scores.
Due to the small number of people classified as ‘mini-
mal’ (PHQ-9, N = 9; GAD-7, N = 11), these results are not 
described but are a limitation of the analysis. Complemen-
tary construct validity analyses at the item-level and using 
the IAPT-PS and WSAS measures are presented in Appen-
dices S6 and 7.
Responsiveness
Ceiling effects at baseline (Table 2) and at all time-points by 
trial-arm (Appendix S4) occurred in a lower proportion of 
responders for the ReQoL-UI/-10 than EQ-5D-5L.
Tables 3 and 6 SRM results suggest responsiveness dif-
fered dependent on time-points being compared relative to 
baseline (e.g. largest SRMs at 9 months across all measures). 
PHQ-9 and GAD-7 responsiveness was generally large. 
EQ-5D-5L scores were relatively more responsive than the 
ReQoL-UI across all time-points assessed, but the ReQoL-
10 tended to be more responsive than its preference-based 
counterparts.
Discussion
In terms of preference-based measures and scores used 
for economic evaluations of interventions for anxiety and 
depression as common comorbid conditions [73], recom-
mending either the EQ-5D-5L (VSE or cross-walk) or 
ReQoL-UI to cover the severity range of both conditions 
does not seem clear-cut based on these results.
For capturing anxiety severity, the recommendation given 
our findings is to use the EQ-5D-5L rather than ReQoL-UI. 
The psychometric properties of the EQ-5D-3L in those with 
anxiety and depression has previously been assessed, the 
general results suggesting construct validity and responsive-
ness for depression, but the results for anxiety severity are 
less convincing [10, 16, 17, 74, 75]. When the EQ-5D-5L 





























































































































































































































































































































































































































































































































































































































































































































































































































































































Table 3  Observed PROM scores, number of responders, and standardised response means by trial-arm and time-points
Measure ti Intervention (I), N = 241 Control (C), N = 120
Time-point (ti) Dif. time-points, ti – t0 Dif. time-points, ti – ti-1 Time-point (ti) Dif. time-points, ti – t0
N (%) Mean (SD) N (%) Mean (SD) SRM N (%) Mean (SD) SRM N (%) Mean (SD) N (%) Mean (SD) SRM
PHQ-9 t0 241 (100) 14.41 (4.94) – – – – – – 120 (100) 14.18 (5.12) – – –
t1 198 (82) 9.28 (5.94) 198 (82) − 5.21 (5.23) − 0.997 198 (82) − 5.21 (5.23) − 0.997 91 (76) 11.58 (5.68) 91 (76) − 2.28 (5.13) − 0.444
t2 186 (77) 8.17 (5.70) 186 (77) − 6.34 (5.43) − 1.168 177 (73) − 0.92 (4.26) − 0.216 – – – – –
t3 182 (76) 7.17 (5.83) 182 (76) − 7.12 (5.90) − 1.206 169 (70) − 0.82 (5.20) − 0.157 – – – – –
t4 177 (73) 6.81 (5.71) 177 (73) − 7.49 (5.94) − 1.261 167 (69) − 0.42 (4.88) − 0.086 – – – – –
t5 173 (72) 6.79 (5.54) 173 (72) − 7.56 (6.38) − 1.184 161 (67) − 0.10 (4.72) − 0.021 – – – – –
GAD-7 t0 241 (100) 12.66 (4.69) – – – – – – 120 (100) 12.54 (4.18) – – –
t1 198 (82) 8.20 (5.31) 198 (82) − 4.50 (5.17) − 0.870 198 (82) − 4.50 (5.17) − 0.870 91 (76) 10.79 (5.12) 91 (76) − 1.63 (4.71) − 0.345
t2 186 (77) 7.38 (5.32) 186 (77) − 5.20 (5.37) − 0.968 177 (73) − 0.58 (4.04) − 0.144 – – – – –
t3 182 (76) 6.93 (5.52) 182 (76) − 5.48 (5.98) − 0.916 169 (70) − 0.28 (4.85) − 0.057 – – – – –
t4 176 (73) 6.48 (5.14) 176 (73) − 5.95 (5.87) − 1.013 166 (69) − 0.35 (4.60) − 0.076 – – – – –
t5 173 (72) 6.08 (4.81) 173 (72) − 6.56 (5.87) − 1.116 160 (66) − 0.65 (4.35) − 0.150 – – – – –
EQ-5D-5L t0 238 (99) 0.735 (0.152) – – – – – – 117 (98) 0.722 (0.182) – – –
VSE t1 198 (82) 0.794 (0.147) 196 (81) 0.058 (0.133) 0.435 196 (81) 0.058 (0.133) 0.435 91 (76) 0.756 (0.181) 89 (74) 0.029 (0.138) 0.212
t2 186 (77) 0.816 (0.149) 184 (76) 0.078 (0.143) 0.547 177 (73) 0.020 (0.106) 0.187 – – – – –
t3 182 (76) 0.830 (0.171) 180 (75) 0.092 (0.168) 0.544 169 (70) 0.013 (0.141) 0.095 – – – – –
t4 176 (73) 0.837 (0.170) 174 (72) 0.096 (0.151) 0.631 166 (69) 0.002 (0.132) 0.019 – – – – –
t5 172 (71) 0.814 (0.172) 170 (71) 0.075 (0.167) 0.451 159 (66) − 0.007 (0.159) − 0.044 – – – – –
EQ-5D-5L t0 238 (99) 0.656 (0.193) – – – – – – 117 (98) 0.645 (0.218) – – –
cross-walk t1 198 (82) 0.723 (0.182) 196 (81) 0.065 (0.178) 0.366 196 (81) 0.065 (0.178) 0.366 91 (76) 0.676 (0.231) 89 (74) 0.020 (0.172) 0.118
t2 186 (77) 0.753 (0.180) 184 (76) 0.090 (0.182) 0.496 177 (73) 0.023 (0.136) 0.171 – – – – –
t3 182 (76) 0.767 (0.212) 180 (75) 0.105 (0.217) 0.483 169 (70) 0.019 (0.178) 0.104 – – – – –
t4 176 (73) 0.779 (0.204) 174 (72) 0.112 (0.196) 0.573 166 (69) 0.007 (0.165) 0.040 – – – – –
t5 172 (71) 0.751 (0.201) 170 (71) 0.092 (0.215) 0.430 159 (66) − 0.009 (0.193) − 0.046 – – – – –
ReQoL-UI t0 237 (98) 0.788 (0.123) – – – – – – 116 (97) 0.757 (0.171) – – –
t1 198 (82) 0.810 (0.140) 195 (81) 0.020 (0.141) 0.138 195 (81) 0.020 (0.141) 0.138 91 (76) 0.793 (0.163) 88 (73) 0.025 (0.139) 0.181
t2 186 (77) 0.836 (0.151) 183 (76) 0.045 (0.152) 0.295 177 (73) 0.022 (0.139) 0.162 – – – – –
t3 182 (76) 0.840 (0.144) 179 (74) 0.050 (0.166) 0.303 169 (70) 0.002 (0.145) 0.015 – – – – –
t4 176 (73) 0.863 (0.124) 173 (72) 0.070 (0.117) 0.599 166 (69) 0.019 (0.142) 0.131 – – – – –
t5 172 (71) 0.850 (0.135) 169 (70) 0.065 (0.138) 0.471 159 (66) − 0.006 (0.127) − 0.049 – – – – –
ReQoL-10 t0 237 (98) 18.52 (6.24) – – – – – – 116 (97) 18.76 (6.75) – – –
t1 198 (82) 21.00 (6.85) 195 (81) 2.20 (6.17) 0.357 195 (81) 2.20 (6.17) 0.357 91 (76) 20.25 (6.40) 88 (73) 0.93 (6.17) 0.151
t2 186 (77) 24.10 (7.36) 183 (76) 5.37 (7.43) 0.723 177 (73) 3.04 (6.46) 0.471 – – – – –
t3 182 (76) 24.59 (7.90) 179 (74) 5.79 (7.95) 0.728 169 (70) 0.27 (7.52) 0.036 – – – – –
t4 176 (73) 25.49 (8.20) 173 (72) 6.66 (7.71) 0.863 166 (69) 0.92 (6.88) 0.134 – – – – –
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in study samples including those with depression and/or 
anxiety, the results have generally suggested the EQ-5D-5L 
improves on the EQ-5D-3L based on reduced ceiling effects, 
and improved discriminatory power (known-group validity) 
and convergent validity [26, 27]; however, due to the inclu-
sion of people with multiple conditions with no anxiety or 
depression-specific measure and use of different statistical 
methods, direct comparison with these studies is difficult.
When comparing the EQ-5D-5L VSE and cross-walk in 
our study, they have similar psychometric results. Within 
the UK, Mulhern et al. [76] compared the UK EQ-5D-3L 
value set, EQ-5D-5L VSE and cross-walk concluding that 
there are important differences, including the distribution of 
the value sets systematically differed (e.g. Appendix S3) and 
the EQ-5D-5L values were higher than EQ-5D-3L/cross-
walk values (e.g. Tables 2 and 3). Despite these identified 
differences, our psychometric results based on VSE and 
cross-walk in terms of construct validity were similar, with 
better responsiveness for the VSE relative to cross-walked 
scores—the suggestion being the preference-based scores 
may play more of a part in the measures’ responsiveness 
than construct validity, which logically make sense given 
the ‘construct’ should stem from the descriptive system but 
‘responsiveness’ will be related to the scoring algorithm 
used.
Compared to the EQ-5D-5L, the ReQoL-UI/-10 clearly 
have better construct validity with depression than anxi-
ety severity. One explanation could be that the GAD-7 is 
focussed on anxiety symptomology, whereas the ReQoL-
UI/-10 departs from symptomology as recovery-focussed 
quality-of-life measures such that by construct design 
they wouldn’t be capturing similar aspects of anxiety; 
although, more symptomatic items are included in the 
ReQoL-20. However, responsiveness was generally small 
for the ReQoL-UI (medium when GAD-7/PHQ-9 > reliable 
change threshold); smaller than for the EQ-5D-5L scores 
and ReQoL-10. Direct comparisons with the psychomet-
ric assessment which suggested the ReQoL-10 performed 
“markedly better than the EQ-5D[-3L]” are difficult, but our 
results suggest the ReQoL-10 generally had better respon-
siveness and construct validity with depression than the EQ-
5D-5L, but not with anxiety severity [18]. The ReQoL-UI’s 
UK value set and less mental health items compared to the 
ReQoL-10 seems to be reducing its relative responsiveness; 
however, as the first study assessing the ReQoL-UI’s psy-
chometric properties, there are currently no comparative 
empirical literature results.
The EQ-5D-5L’s single mental health ‘anxiety/depres-
sion’ item captured anxiety and depression constructs differ-
ently, generally having better construct validity with anxiety 
than depression severity. This item-level result has been sug-
gested by previous studies, albeit suggesting the item cap-
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anxiety, but certainly not equally across constructs [48, 49]. 
When assessing convergent validity at the item-level par-
ticularly for the preference-based measures, specific items 
are potentially driving the convergent validity results before 
accounting for the influence of the preference-based scores 
(e.g. EQ-5D-5L’s ‘anxiety/depression’ item with GAD-7 
items and score)—see Appendix S6.
Reimbursement and policy implications
The results of this study highlight a range of considerations 
when using and interpreting scores from the EQ-5D-5L and 
ReQoL-UI (-10), and their subsequent effect on economic 
evaluation (or clinical assessment) evidence. We shall focus 
on two implications from a reimbursement and policy per-
spective, particularly associated with NICE given our focus 
on England/UK value sets and cross-walk.
First, our results suggest the VSE has marginally better 
psychometric properties over the NICE recommended cross-
walk for capturing the impact of anxiety and/or depression 
severity [37]. However, these results are perhaps not suf-
ficient to make NICE change their interim position at this 
time given the ongoing debate around the VSE for which 
there is a new valuation study [35, 36, 39, 40, 46]. Further 
work is required to understand how the EQ-5D-5L (VSE 
and cross-walk) and ReQoL-UI impact on QALY and sub-
sequent cost-effectiveness estimates provided to decision-
makers (the current authors are assessing this aspect for a 
future publication).
Secondly, different preference-based measures, value sets 
and cross-walk algorithms produce different QALYs [77, 
78], which is partly behind NICE’s EQ-5D-3L reference 
case to produce directly comparable results [13, 37]. How-
ever, agencies like NICE state alternative preference-based 
measures can be used if supported by empirical evidence, 
such as comparative psychometric results [13]. Here we sug-
gest the EQ-5D-5L (VSE and cross-walk) better captures 
anxiety severity with better responsiveness than the ReQoL-
UI. As the NICE preferred measure, there is no suggestion 
to choose the ReQoL-UI over the EQ-5D-5L if only one can 
be chosen to capture anxiety severity (this will be down to 
researchers, patients and public representatives to deliber-
ate the extra cognitive burden of additional questions on 
the patient group of interest). For depression severity, the 
ReQoL-UI’s better construct validity, despite its poorer 
responsiveness, may be enough to rationalise its use over 
the EQ-5D-5L; noting depression severity will be notably 
better represented than anxiety severity by the ReQoL-UI 
and responsiveness is important particularly for economic 
evaluation. However, the ReQoL-10 offers both a clinical 
and preference-based measure, which could capture addi-
tional information important to patients, clinicians, and 
decision-makers.
Additionally, the ReQoL measures are designed to depart 
from symptomology to broader recovery-focussed quality of 
life. Although PHQ-9 and GAD-7 measures are used to cap-
ture symptomology in IAPT service users with ‘[symptom] 
recovery’ representing a change from ‘caseness’ to ‘no case-
ness’, a shift in paradigm to these broader ‘personal recov-
ery’ aspects could change the interpretation of our results if 
the symptoms and severity aspects captured by the GAD-7 
and PHQ-9 were no longer the outcomes of interest for men-
tal health services and users.
International generalisability
The generalisability of our England/UK-based results to 
other countries requires reflecting on existing between coun-
try considerations of value sets, cross-walk algorithms, and 
descriptive systems. For example, Gerlinger et al. [79] com-
pared EQ-5D-5L value sets across six different countries 
(Canada, England, Japan, Korea, Netherlands, and Uruguay) 
and 10 different cross-walk algorithms: “There were sub-
stantial differences in the [value set] utility index between 
Table 4  Correlation coefficient matrix between measure scores at baseline
EQ-5D-5L EQ-5D Five-Level version, GAD-7 Generalised Anxiety Disorder-7, PHQ-9 Patient Health Questionnaire-9, ReQoL-UI(-10) Recov-
ering Quality of Life—Utility Index (10 item)
Cohen’s ACS cut-offs: weak, < 0.3; moderate, 0.3 < 0.5; strong, ≥ 0.5








 PHQ-9 − 0.391 (< 0.001) − 0.382 (< 0.001) − 0.529 (< 0.001) − 0.576 (< 0.001) 0.346 (< 0.001)
 GAD-7 − 0.408 (< 0.001) − 0.411 (< 0.001) − 0.339 (< 0.001) − 0.331 (< 0.001) 0.514 (< 0.001)
Recovery-focussed
 ReQoL-UI 0.601 (< 0.001) 0.597 (< 0.001) – – − 0.394 (< 0.001)









Table 5  Testing known-group validity based on condition-specific cut-off groups at baseline
Clin. Clinical, ES effect size (Cohen’s d), EQ-5D-5L EQ-5D Five Dimension Five Level version, GAD-7 Generalised Anxiety Disorder 7, Gen. Pop. general population, Mod. Sev. moderately 
severe, N number of people, PHQ-9 Patient Health Questionnaire 9, ReQoL-10 Recovering Quality of Life—10 item, ReQoL-UI Recovering Quality of Life—Utility Index, SD standard devia-
tion
Cohen’s AES cut-off: trivial, < 0.2; small, 0.2 < 0.5; medium, 0.5 < 0.8; large; ≥ 0.8; an ES of > 1 means the difference between the two means is larger than one standard deviation. ESs are rela-
tive to less severe group
p-values: calculated from the non-parametric Kruskal Wallis test to suggest if there is a statistically significant difference between two or more known-groups based on the scores used as a com-




















PHQ-9 No Caseness, < 10 65 (18.0) 0.785 (0.164) 0.712 (0.202) 0.854 (0.099) 24.219 (6.632) 3.092 (0.843)
Caseness, ≥ 10 296 (82.0) 0.718 (0.160) 0.413 0.639 (0.200) 0.364 0.761 (0.143) 0.688 17.353 (5.646) 1.177 3.297 (0.820) − 0.248
(< 0.001) (< 0.001) (< 0.001) (< 0.001) (0.052)
Minimal, < 5 9 (2.5) 0.847 (0.095) 0.791 (0.107) 0.935 (0.036) 31.625 (4.274) 3.000 (0.707)
Mild, 5–9 56 (15.5) 0.775 (0.171) 0.440 0.699 (0.211) 0.455 0.843 (0.100) 0.970 23.161 (6.240) 1.399 3.107 (0.867) − 0.126
Moderate, 10–14 117 (32.4) 0.786 (0.115) − 0.082 0.723 (0.140) − 0.146 0.821 (0.089) 0.230 20.104 (4.903) 0.569 2.966 (0.658) 0.193
Mod. Sev., 15–19 120 (33.2) 0.710 (0.164) 0.535 0.629 (0.203) 0.541 0.751 (0.138) 0.608 16.739 (5.198) 0.666 3.328 (0.832) − 0.483
Severe, ≥ 20 59 (16.3) 0.599 (0.159) 0.684 0.490 (0.205) 0.685 0.661 (0.177) 0.594 13.186 (4.950) 0.694 3.897 (0.742) − 0.708
(< 0.001) (< 0.001) (< 0.001) (< 0.001) (< 0.001)
GAD-7 No Caseness, < 8 51 (14.1) 0.787 (0.126) 0.726 (0.157) 0.823 (0.077) 20.160 (5.811) 2.706 (0.807)
Caseness, ≥ 8 310 (85.9) 0.721 (0.166) 0.409 0.640 (0.206) 0.431 0.770 (0.148) 0.377 18.340 (6.465) 0.285 3.352 (0.795) − 0.811
(0.020) (0.016) (0.035) (0.044) (< 0.001)
Minimal, < 5 11 (3.0) 0.815 (0.124) 0.764 (0.147) 0.860 (0.064) 21.182 (5.269) 2.455 (0.688)
Mild, 5–9 81 (22.4) 0.794 (0.136) 0.156 0.728 (0.179) 0.207 0.826 (0.093) 0.378 21.438 (6.566) − 0.040 2.815 (0.792) − 0.461
Moderate, 10–14 146 (40.4) 0.752 (0.162) 0.275 0.685 (0.184) 0.232 0.794 (0.124) 0.283 18.851 (5.914) 0.420 3.182 (0.698) − 0.500
Severe, ≥ 15 123 (34.1) 0.654 (0.155) 0.615 0.552 (0.201) 0.693 0.719 (0.169) 0.509 16.190 (6.064) 0.445 3.725 (0.756) − 0.749
(< 0.001) (< 0.001) (< 0.001) (< 0.001) (< 0.001)
Recovery-focussed quality of life
ReQoL-10 Clin. range, < 24 281 (79.6) 0.707 (0.167) 0.624 (0.208) 0.746 (0.141) 16.224 (4.480) 3.361 (0.826)
Gen. Pop., ≥ 24 72 (20.4) 0.823 (0.101) − 0.743 0.766 (0.119) − 0.733 0.899 (0.044) − 1.199 27.861 (3.825) − 2.672 2.861 (0.718) 0.620









Table 6  Standardised response means (SRM)—intervention-arm participants grouped dependent on reliable change in PHQ-9 or GAD-7 score since baseline
Groupings based on what is classified as a reliable change (Δ) in score, which for the PHQ-9 is an absolute score value of ≥ 6 [67] and for the GAD-7 is an absolute score value of ≥ 4 [67]
Cohen’s SRM cut-off: < 0.2, trivial; 0.2 < 0.5, small; 0.5 < 0.8, medium; ≥ 0.8, large; an SRM of > 1 means the change in score between time-points is larger than one standard deviation
EQ-5D-5L EQ-5D Five Dimension Five Level version, GAD-7 Generalised Anxiety Disorder 7, N number of people, PHQ-9 Patient Health Questionnaire 9, ReQoL-10 Recovering Quality of 
Life—10 item, ReQoL-UI Recovering Quality of Life—Utility Index, SD standard deviation, SRM standardised response mean
Measure ti PHQ-9 PHQ-9 GAD-7
GAD-7 PHQ-9 Δ ≤ − 6 PHQ-9 Δ − 6 < 6 GAD-7 Δ ≤ − 4 GAD-7 Δ − 4 < 4
N (%) N (%) Mean (SD) SRM N (%) Mean (SD) SRM N (%) Mean (SD) SRM N (%) Mean (SD) SRM
EQ-5D-5L t1–t0 196 (81) 85 (43) 0.102 (0.138) 0.734 109 (56) 0.029 (0.116) 0.252 109 (56) 0.088 (0.136) 0.647 79 (40) 0.021 (0.122) 0.175
VSE t2–t0 184 (76) 103 (56) 0.115 (0.134) 0.856 79 (43) 0.032 (0.141) 0.231 115 (63) 0.112 (0.131) 0.855 61 (33) 0.037 (0.141) 0.259
t3–t0 180 (75) 109 (61) 0.136 (0.157) 0.865 68 (38) 0.035 (0.137) 0.258 114 (63) 0.129 (0.159) 0.815 54 (30) 0.064 (0.118) 0.538
t4–t0 174 (72) 114 (66) 0.129 (0.136) 0.943 58 (33) 0.044 (0.151) 0.291 118 (68) 0.123 (0.132) 0.930 49 (28) 0.054 (0.174) 0.310
t5–t0 170 (71) 107 (63) 0.112 (0.141) 0.794 58 (34) 0.027 (0.185) 0.145 122 (72) 0.110 (0.139) 0.792 39 (23) 0.012 (0.200) 0.061
EQ-5D-5L t1–t0 196 (81) 85 (43) 0.118 (0.182) 0.648 109 (56) 0.031 (0.156) 0.201 109 (56) 0.104 (0.182) 0.573 79 (40) 0.017 (0.165) 0.105
cross-walk t2–t0 184 (76) 103 (56) 0.135 (0.164) 0.823 79 (43) 0.035 (0.191) 0.183 115 (63) 0.132 (0.163) 0.808 61 (33) 0.039 (0.190) 0.205
t3–t0 180 (75) 109 (61) 0.153 (0.208) 0.735 68 (38) 0.052 (0.174) 0.302 114 (63) 0.149 (0.203) 0.731 54 (30) 0.080 (0.174) 0.462
t4–t0 174 (72) 114 (66) 0.150 (0.170) 0.884 58 (33) 0.052 (0.215) 0.243 118 (68) 0.144 (0.178) 0.812 49 (28) 0.070 (0.205) 0.340
t5–t0 170 (71) 107 (63) 0.132 (0.189) 0.699 58 (34) 0.048 (0.234) 0.207 122 (72) 0.135 (0.186) 0.727 39 (23) 0.011 (0.247) 0.043
ReQoL-UI t1–t0 195 (81) 85 (44) 0.048 (0.144) 0.334 108 (55) − 0.001 (0.137) − 0.009 109 (56) 0.037 (0.143) 0.262 78 (40) − 0.006 (0.131) − 0.049
t2–t0 183 (76) 103 (56) 0.087 (0.134) 0.646 78 (43) − 0.008 (0.159) − 0.052 115 (63) 0.074 (0.145) 0.510 60 (33) 0.005 (0.145) 0.036
t3–t0 179 (74) 109 (61) 0.085 (0.159) 0.533 67 (37) 0.006 (0.158) 0.037 113 (63) 0.087 (0.155) 0.563 54 (30) − 0.001 (0.159) − 0.006
t4–t0 173 (72) 113 (65) 0.102 (0.096) 1.059 58 (34) 0.012 (0.129) 0.096 116 (67) 0.094 (0.103) 0.911 50 (29) 0.038 (0.125) 0.303
t5–t0 169 (70) 108 (64) 0.097 (0.134) 0.729 56 (33) 0.013 (0.129) 0.103 122 (72) 0.091 (0.121) 0.748 38 (22) 0.000 (0.168) − 0.003
ReQoL-10 t1–t0 195 (81) 85 (44) 4.506 (7.243) 0.622 108 (55) 0.500 (4.423) 0.113 109 (56) 3.385 (6.409) 0.528 78 (40) 0.590 (5.740) 0.103
t2–t0 183 (76) 103 (56) 8.359 (7.097) 1.178 78 (43) 1.679 (5.839) 0.288 115 (63) 7.174 (7.430) 0.966 60 (33) 2.367 (6.460) 0.366
t3–t0 179 (74) 109 (61) 8.817 (7.961) 1.107 67 (37) 1.403 (4.939) 0.284 113 (63) 8.310 (7.500) 1.108 54 (30) 2.352 (6.519) 0.361
t4–t0 173 (72) 113 (65) 9.124 (7.558) 1.207 58 (34) 2.155 (5.448) 0.396 116 (67) 8.586 (7.752) 1.108 50 (29) 3.160 (6.089) 0.519
t5–t0 169 (70) 108 (64) 8.361 (7.245) 1.154 56 (33) 2.214 (6.050) 0.366 122 (72) 7.705 (7.159) 1.076 38 (22) 1.868 (7.018) 0.266
EQ-5D-5L t1–t0 196 (81) 85 (43) − 1.000 (1.000) − 1.000 109 (56) − 0.349 (0.786) − 0.443 109 (56) − 0.881 (1.007) − 0.875 79 (40) − 0.304 (0.774) − 0.393
depression t2–t0 184 (76) 103 (56) − 1.010 (0.923) − 1.093 79 (43) − 0.494 (0.998) − 0.494 115 (63) − 1.035 (0.936) − 1.106 61 (33) − 0.443 (0.922) − 0.480
/anxiety t3–t0 180 (75) 109 (61) − 1.312 (0.978) − 1.341 68 (38) − 0.471 (0.969) − 0.486 114 (63) − 1.272 (0.989) − 1.286 54 (30) − 0.648 (0.935) − 0.693
item t4–t0 174 (72) 114 (66) − 1.333 (0.899) − 1.483 58 (33) − 0.483 (1.047) − 0.461 118 (68) − 1.280 (0.995) − 1.286 49 (28) − 0.592 (0.956) − 0.619
t5–t0 170 (71) 107 (63) − 1.215 (0.911) − 1.333 58 (34) − 0.621 (1.089) − 0.570 122 (72) − 1.230 (0.907) − 1.355 39 (23) − 0.359 (1.088) − 0.330
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countries in the values attributed to each health state”; a 
suggestion also made related to cross-walked scores. It is dif-
ficult to hypothesise exactly how psychometric performance 
might change between country-specific value sets and cross-
walk algorithms, noting that part of the psychometric prop-
erties comes from the underlying descriptive system which 
will remain (hopefully) intact across countries. Although 
translation and subsequent interpretation of the descriptive 
system could impact on results, it seems reasonable to sug-
gest the construct validity results which stem more from the 
measures’ descriptive system may be generalisable, but the 
responsiveness results are more country specific dependent 
on value set and cross-walk algorithm used while noting the 
limitation of our indirect comparison [80].
Limitations
These trial eligible participants represent a specific mental 
health population referred to IAPT Step 2 care, England; 
therefore, they do not represent the full range of anxiety 
and/or depression severity (i.e. few had ‘minimal’ severity, 
restricting analysis at this level). The sample size is greater 
than the ‘rules of thumb’ for the analyses conducted [81]; 
however, larger and more representative samples of patients 
with depression and anxiety, using alternative measures 
alongside the GAD-7 and PHQ-9 (e.g. HADS; BDI-II) for 
comparison and in diverse settings (e.g. secondary men-
tal health care), should be sought. Without a gold stand-
ard, indirect methods are used to support the psychomet-
ric results. If there is a shift from ‘symptom recovery’ to 
broader ‘personal recovery’ within mental health services 
like IAPT, the ReQoL measures purport to measure this con-
struct and therefore condition-specific, more symptom-based 
measures like the GAD-7 and PHQ-9 may not represent the 
construct of interest which form the basis on this psycho-
metric analysis.
Conclusion
ReQoL-UI/-10 had better construct validity with depression 
severity (PHQ-9) than the EQ-5D-5L (VSE and cross-walk 
scores), which had relatively better construct validity with 
anxiety severity (GAD-7) than the ReQoL-UI/-10. EQ-
5D-5L score responsiveness (VSE particularly) was better 
than ReQoL-UI, but worse than ReQoL-10. EQ-5D-5L anxi-
ety/depression item had better construct validity with anxi-
ety than depression severity. There is insufficient evidence to 
suggest using the ReQoL-UI over EQ-5D-5L for economic 
evaluations to capture anxiety severity. However, there 
may be rationale to use the ReQoL-UI to capture depres-
sion severity given its better construct validity, albeit poorer 
responsiveness, and if ‘personal recovery’ relative to change 
in symptomology is the construct/outcome of interest for 
mental health services and users.
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